Skip to content

Clinical observation of therapeutic effect on acne vulgaris of cold atmospheric plasma gel

Clinical observation of therapeutic effect on acne vulgaris of cold atmospheric plasma gel

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200062851
Enrollment
Unknown
Registered
2022-08-20
Start date
2022-08-20
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Interventions

Group A:cold atmospheric plasma PLEL gel+viaminate capsules+clarithromycin sustained-release tablets
Group B:cold atmospheric plasma PAG gel+viaminate capsules+clarithromycin sustained-release tablets
Group C:PLEL gel+viaminate capsules+clarithromycin sustained-release tablets
Group :PAG gel+viaminate capsules+clarithromycin sustained-release tablets
control group:viaminate capsules+clarithromycin sustained-release tablets

Sponsors

Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-40 years, male and female unlimited; 2. Patients with acne vulgaris were diagnosed according to diagnostic criteria; 3. Skin lesions are mainly located on the face; 4. Vital signs stable; 5. To sign the informed consents.

Exclusion criteria

Exclusion criteria: 1. Medication Acne;occupational acne; post adolescent acne or acne fulminans; 2. Patients are diagnosed as other active skin diseases that may affect the evaluation; 3. Received systematic treatments or corticosteroid drugs in 8 weeks, treated with antibacterial agents or retinoic acids in 4 weeks; 4. Severe allergic constitution, allergic to known drugs in the study or contraindicated; 5. Patients with severe liver or kidney dysfunction, cardiopulmonary insufficiency, serious diseases of digestive tract or blood system; 6. A history of hepatitis b or c, or HIV antibody positive; 7. A history of severe systemic disease, malignant tumor or mental illness; 8. The female patients who are pregnant or in the suckling periods; 9. Patients who dropped out or did not follow the established experimental plan for some reason; 10. Other conditions that the researchers considered inappropriate for participation in the study.

Design outcomes

Primary

MeasureTime frame
GAGS, Global Acne Grading System;

Secondary

MeasureTime frame
Dermatology Life Quality Index;

Countries

China

Contacts

Public ContactXia Yumin

Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University

baidoudou0523@stu.xjtu.edu.cn+86 18891529053

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026